GlassScriptPhysician profile
Douglas B Masson
NPI 1114901238
$21,821.26
in general payments reported to CMS, 2019-2025
45 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 81% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,043 · 2020: $1,030 · 2021: $2,433 · 2022: $2,609 · 2023: $4,060 · 2024: $2,540 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856 · Education: $1,500 · Travel and Lodging: $1,225 · Consulting Fee: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,856.16 |
| Education | $1,500.00 |
| Travel and Lodging | $1,225.33 |
| Consulting Fee | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $8,448.41 | 2019-2025 | Rezum Generator, Axonics, Bulkamid |
| Axonics, INC. | $4,804.51 | 2021-2024 | Bulkamid, Axonics |
| Coloplast Corp | $2,980.08 | 2019-2024 | Speedicath |
| Intuitive Surgical, INC. | $1,741.90 | 2019-2025 | |
| Astellas Pharma US INC | $511.19 | 2019-2022 | |
| Medtronic, INC. | $380.87 | 2022-2025 | Interstim |
| Pfizer INC. | $311.98 | 2019-2024 | |
| Urogen Pharma, INC. | $271.05 | 2020-2024 | |
| Endo Pharmaceuticals INC. | $225.18 | 2019-2023 | Xiaflex, Aveed, Edex |
| Myriad Genetic Laboratories, INC. | $209.25 | 2021-2023 | Prolaris |
| Bard Peripheral Vascular, INC. | $167.83 | 2022 | |
| Urovant Sciences INC | $159.23 | 2022 | |
| Janssen Biotech, INC. | $144.34 | 2019-2023 | Erleada |
| Wright Medical Technology, INC. | $117.41 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.26 | 2019-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Masson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.